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Purpose: To determine the contribution of copy number variation (CNV) in the regulation of complement activation
(RCA) locus to the development of age-related macular degeneration (AMD).
Methods: A multiplex ligation-dependent probe amplification assay was developed to quantify the number of copies of
CFH, CFHR3, CFHR1, CFHR4, CFHR2, and CFHR5 in humans. Subjects with (451) and without (362) AMD were
genotyped using the assay, and the impact on AMD risk was evaluated.
Results: Eight unique combinations of copy number variation were observed in the 813 subjects. Combined deletion of
CFHR3 and CFHR1 was protective (OR=0.47, 95% confidence interval 0.36–0.62) against AMD and was observed in
88 (82 [18.6%] with one deletion, 6 [1.4%] with two deletions) subjects with AMD and 127 (108 [30.7%] with one deletion,
19 [5.4%] with two deletions) subjects without AMD. Other deletions were much less common: CFH intron 1 (n=2),
CFH exon 18 (n=2), combined CFH exon 18 and CFHR3 (n=1), CFHR3 (n=2), CFHR1 (n=1), combined CFHR1 and
CFHR4 (n=15), and CFHR2 deletion (n=7, 0.9%). The combined CFHR3 and CFHR1 deletion was observed on a common
protective haplotype, while the others appeared to have arisen on multiple different haplotypes.
Conclusions: We found copy number variations of CFHR3, CFHR1, CFHR4, and CFHR2. Combined deletion of
CFHR3 and CFHR1 was associated with a decreased risk of developing AMD. Other deletions were not sufficiently
common to have a statistically detectable impact on the risk of AMD, and duplications were not observed.
Complement factor H (gene, CFH; protein, factor H) is
the  main  inhibitor  of  the  alternative  pathway  of  the
complement system [1]. Dysfunction of factor H is associated
with increased liability to infections and chronic diseases,
such as type II membranoproliferative glomerulonephritis,
atypical hemolytic uremic syndrome, and age-related macular
degeneration (AMD) [2].
The  300,000  bp  regulation  of  complement  activation
(RCA) locus on chromosome 1q32 contains CFH and five
ancestrally related genes that lie in a head-to-tail arrangement
(Figure  1).  The  five  genes  code  for  proteins  that  show
sequence and structural homology to CFH and factor H. They
are referred to as complement factor H-related (CFHR) genes
and  are  numbered  one  through  five.  CFH  and  the  five
CFHR genes are thought to have developed by successive
duplications within the RCA locus.
Genetic  variation  in  genes  encoding  proteins  for  the
alternative pathway of complement plays a major role in the
development of AMD [3-8], which is the leading cause of
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vision loss in elderly individuals of the developed world [9].
Copy number variations in the form of deletions of CFHR3
and CFHR1 within the RCA locus have been reported to
contribute to the development of AMD [10-13]. Because of
the extensive linkage disequilibrium in the RCA locus, it has
been difficult to determine if the CFHR proteins have a role
in AMD independent of factor H, using statistical genetic
approaches.
The  amino  acid  sequence  of  the  CFHR  proteins  is
homologous to factor H, with the main difference being the
presence or absence of different protein domains in the full
length factor H. For example, CFHR3 is similar to factor H,
except  that  it  lacks  the  N-terminal  protein  domains  that
downregulate the alternative pathway. Thus, the protective
effect  of  the  common  combined  deletion  of  CFHR3  and
CFHR1 is thought to occur through decreased competition of
CFHR3 with factor H for binding to complement proteins
[11,13].  CFHR1  was  reported  to  inhibit  the  terminal
complement  pathway  and  thus  might  be  involved  in  the
pathogenesis of AMD [14]. CFHR4 interacts with native C-
reactive protein (CRP), thereby enhancing opsonization via
binding to CRP, which is elevated in the choroid and blood of
subjects  with  AMD  [15].  Also,  variants  in  CFHR2  and
CHR5 [16] have been demonstrated to be associated with
AMD [17].
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Figure 1. Multiplex ligation probe amplification strategy to quantify copy number variation across the regulation of complement activation
locus, which is shown in panel A. It comprises complement factor H (CFH) and the five CFH related genes (CFHR1–CFHR5). Panels B to
H describe the MLPA assays. The forward primer (FWP) is attached to the left oligonucleotide (LO), while the right oligonucleotide (RO) is
attached to the reverse primer (RVP). The oligonucleotide pairs were designed to hybridize specifically to intron 1 of CFH (B), exon 18 of
CFH (C), exon 3 of CFHR3 (D), exon 3 of CFHR1 (E), exon 2 of CFHR4 (F), intron 3B of CFHR2 (G), and exon 7 of CFHR5 (H). Capital
letters in the wild-type sequence from the National Center for Biotechnology Information (NCBI) correspond to exons, while lower case
indicates introns. The MLPA procedure was described previously [12].We report an analysis of copy number variation across
the  entire  RCA  locus  and  its  possible  contribution  to  the
development of AMD. To overcome the extensive homology
between the five CFHR genes, we developed an assay (Figure
1) using the multiplex ligation-dependent probe amplification
(MLPA) technique [12,18-20]. We demonstrated that eight
deletions  of  the  CFHR  genes  segregate  in  the  Caucasian
population and we describe the haplotype backgrounds on
which these deletions occur and their association with AMD.
METHODS
Subjects: The study followed the tenets of the Declaration of
Helsinki, was approved by the institutional review board of
the  Mayo  Clinic  (Rochester,  MN),  and  written  informed
consent was obtained from all subjects after explanation of the
nature and possible consequences of the study. The subjects
were composed of the 813 self-reported Caucasian individuals
described in Table 1. The ascertainment and characterization
of  the  subjects  has  been  reported  [21].  Diagnosis  was
determined by review of fundus photographs as described
previously [8,12,22-24]. Briefly, all subjects diagnosed with
AMD had large drusen (≥125 µ) with sufficient drusen area
to fill a 700-µ circle or more advanced findings. Controls had
five or fewer hard drusen (<63 µ) without pigment changes or
more advanced findings. Geographic atrophy and exudation
were defined using the Wisconsin age-related maculopathy
grading  system  [25].  Subjects  have  been  graded  multiple
independent times by two individual highly qualified retina
specialists [21]. Subjects with both neovascular and primary
geographic atrophy, namely the development of geographic
atrophy before the onset of exudation, were included in the
analysis for each subtype. When a unique grade for each
subject was required, the subjects graded “both” were added
to the grade with a smaller number of subjects (geographic
atrophy) to increase power [12,21,26].
Multiplex ligation-dependent probe amplification:
Design  of  oligonucleotides—Oligonucleotides  for
MLPA were designed to bind specifically to CFH (intron 1),
CFH (exon 18), CFHR3 (exon 3), CFHR1 (exon 3), CFHR4
(exon 2), CFHR2 (intron 3), and CFHR5 (exon 7); Figure 1.
Control oligonucleotides binding to the apoptosis-inducing
factor mitochondrion-associated 1 (PDCD8 (AIFM1)) on the
X  chromosome  and  synovial  sarcoma  translocation
chromosome  18  (SS18)  on  chromosome  18  were  also
designed and included. The oligonucleotide pairs consisted of
a left oligonucleotide (LO) and a right oligonucleotide (RO).
The  pairs  were  designed  1)  to  have  their  ligation  point
specifically at a known sequence variation of the homologous
genes as described in Figure 1, 2) to have a 4-bp difference in
length for each gene of interest, ranging from 100 to 132 bp,
and  3)  to  have  a  GC  content  of  40%–60%.  To  allow
quantitative  analysis  with  capillary  electrophoresis,  the
forward primer in the PCR was labeled with a fluorescent 6-
carboxy-fluorescine (FAM) marker at the 5′ end. To avoid
quenching of the fluorescent FAM marker by the G base, the
standard MLPA forward primer [18,20] was redesigned and
the sequence is shown in Figure 1. The oligonucleotides and
the primers were obtained from Integrated DNA Technology
(Coralville, IA; Table 2).
Assay conditions for MLPA—We performed MLPA
according to the MLPA protocol using the MLPA EK kit
(MRC-Holland, Amsterdam, Netherlands) and 50 ng DNA
per sample. Four control samples (two male and two female)
without deletions of CFH and CFHR1–5, based on the MLPA
assay, and a water (no DNA) control were included in each
experiment.  Hybridization,  ligation,  and  the  setup  for
amplification  of  the  MLPA  assay  were  performed  as
described previously [12]. Amplification conditions were 30
cycles at 95 °C for 30 s, 60 °C for 30 s, and 72 °C for 60 s,
followed by 20 min at 72 °C and a hold at 4 °C.
Assay conditions for capillary electrophoresis—Two
microliters of the amplified products were diluted (1:30) in
58 µl of distilled water, of which 2 µl was plated into a well
with 18 µl of a mixture of 1 part formamide Hi-Di (Applied
Biosystems, Foster City, CA) and 0.015 parts GeneScan 120
LIZ  size  standard  (Applied  Biosystems).  Capillary
electrophoresis  was  performed  on  an  Applied  Biosystems
3730  DNA  Analyzer  (Applied  Biosystems)  as  described
previously [12]. If the detection threshold was crossed, the
amplified product was diluted in distilled water (1:50) and 2 µl
of the dilution was used for capillary electrophoresis. If the
TABLE 1. DEMOGRAPHIC AND CLINICAL FEATURES OF THE SUBJECTS.
Subjects Number Age (mean±standard deviation) Male:Female ratio
Controls 362 70.4±8.1 0.74
AMD subtotal 451 77.6±8.8 0.46
Early AMD 210 75.1±9.4 0.43
Geographic atrophy* 84 80.1±5.7 0.65
Exudative AMD 157 79.5±8.5 0.43
Total subjects 813 74.4±9.2 0.58
        Twenty-two subjects who had both primary geographic atrophy and exudative age related macular degeneration (AMD; category
        “Both”) were included in the geographic atrophy group as described in methods.
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product was used for capillary electrophoresis.
Data  analysis—GeneMapper  Software  v4.0  (Applied
Biosystems) was used to perform fragment sizing with the
internal 120 LIZ size standard, automated peak calling, and
peak normalization [27]. The nine peak heights of the nine
probes  (CFH1  [CFH  intron  1],  CFH18  [CFH  exon  18],
CFHR3,CFHR1,CFHR4,CFHR2,CFHR5,PDCD8,  and
SS18) of each sample were exported for further data analysis.
The peak heights were normalized by dividing each peak
height by the sum of all nine peak heights in each sample. Each
normalized peak height was divided by the means of that peak
height in the four control samples to standardize the peak
heights to the control samples included in every run. The ratio
for  the  probes
CFH1,CFH18,CFHR3,CFHR1,CFHR4,CFHR2,CFHR5,
and PDCD8 of every sample was generated by dividing the
normalized and standardized peak heights of the probe by the
normalized and standardized peak height of the control probe
SS18  in  that  sample.  The  probe  of  the  X  chromosome
(PDCD8) was used as a control for unintended interchange of
samples and as a model of deletions. Each assay run was
calculated separately due to possible interassay variations, as
recommended [18]. The person performing the assay and the
calculations was masked to the ophthalmologic diagnosis of
the subjects [12].
Replication of MLPA assay results—The MLPA assay
was performed three times on all samples. A sample was
defined as having “failed” if i) a result was not repeated a
second time, ii) the SS18 control probe did not result in two
alleles, and iii) the gender of the sample did not match the
number of alleles of the control probe PDCD8 (i.e., a male
subject should only have one copy, while a female subject
should have at least two copies of the PDCD8 gene). Selected
samples were repeated using the TaqMan quantitative PCR
assay (Applied Biosystems).
TaqMan  assay:  A  TaqMan  assay  was  performed  to
independently confirm the copy number variation of eight
randomly  selected  samples.  Specific  genomic  targets  in
CFH (intron 1), CFH (intron 18), CFHR3 (exon 3), CFHR1
(exon 3), CFHR4 (intron 2), CFHR2 (intron 3), and CFHR5
(exon 7) were amplified using the TaqMan Gene Expression
Master Mix (Applied Biosystems) combined with the specific
target gene assay mix consisting of a 0.25-mM TaqMan MGB
probe and 0.9 mM of each PCR primer [12]. Forward primer
5′-TGT  TTT  GCC  AAC  GGA  CCT  ATT  TAG  T-3′  and
reverse primer 5′-GCC CAT TAA TAG GAG CAT TTA TTT
TGC T-3′ was employed for CFHR3. Forward primer 5′-ACA
TCT CCA ATT TAG ATC CTT TGA TTA ACC A-3′ and
reverse primer 5′-GCA TTT TCT TAG TGA ATA AGC AAA
GAT TTA AAA ACA-3′ was used for CFHR1. The TaqMan
assay used for CFH (intron 1) was localized at 194890541;
for CFH (exon 18) it was localized at intron 18 at 194976628;
for CFHR4 it was at intron 2 at 195139068; for CFHR2 it was
at intron 3 at 195188714; and for CFHR5 it was at exon 7 at
195234027. TaqMan probes and primers were obtained from
Applied  Biosystems.  All  reactions  were  performed  in
triplicate, as described previously [12]. The values obtained
for  CFH1,CFH18,CFHR3,CFHR1,CFHR4,CFHR2,  and
CFHR5 copy numbers were normalized to the endogenous
TABLE 2. TARGET SEQUENCES OF THE OLIGONUCLEOTIDES USED IN THE MLPA ASSAY.
Target
Gene
Oligonucleotide
side
MLPA Oligonucleotides (5′ - 3′) hybridization sequences* Product length
(bp)
CFH LO gcctccttgttttaacagtctggct 100
(Intron 1) RO P-cagggggtcactgcaggctactaagaattgggt
CFHR3 LO CAAAAGCGCAGACCACAGTTACATGTAC 104
(Exon 3) RO P-GGAGAAAGGCTGGTCTCCTACTCCCAGATGCATC
CFH LO GTCAGACAGTTATCAGTATGGAGAAGAAGTTAC 108
(Exon 18) RO P-GTACAAATGTTTTGAAGGTTTTGGAATTGATGG
CFHR1 LO CAACATTTCATGTGTAGAACGGGGCTGGTCCACC 112
(Exon 3) RO P-CCTCCCAAATGCAGGTCCACTGgtaagtacaatgct
CFHR4 LO CAGAAATTCAACATGGAGGTCTATATTATAAGAGTT 116
(Exon 2) RO P-TGCGTAGACTATACTTTCCAGCAGCTGCAGGACAATCT
CFHR2 LO cagggattagtacagtgcaatctctgggggctgttattcc 120
(Intron 3B) RO P-gtttacaacaccatgcaataaccttatatgaataaagc
CFHR5 LO CAACACACCAACTTAAGAGGTGCAAAATAGCAG 124
(Exon 7) RO P-GAGTTAATATAAAAACATTACTCAAGCTATCTGGGAAAGAATTTAATCA
PDCD8 LO CGCAAATACAACAGGTATCAGAACTGCTGGCCCCAGATTAAG 128
(Exon 8) RO P-CTTCAGATGGTGAACTCTGTGCACTTCCACCCATGCAGTCACCT
SS18 LO GGCAATCATATGATGGGTCAGAGACAGATTCCTCCCTATAGAC 132
(Exon 6) RO P-CTCCTCAACAGGgtaagattccatttggaaaatttgctacttaatgt
        *Sequences within an exon are shown in upper case, while sequences in introns are presented in lower case. The LO begins
        with the forward primer sequence 5′-TGG GTC CCT AAG GGT TGG A-3′ followed by the sequence shown in the table. The
        5′-end of the RO is phosphorylated (P) and the sequence shown in the table is followed by the complement of the reverse primer
        5′-TCT AGA TTG GAT CTT GCT GGC AC-3′. Figure 1 and the methods provide additional details.
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number of control samples using the ΔΔCT method [28].
Genotyping:  Single  nucleotide  polymorphisms  (SNPs)
tagging  common  haplotypes  across  the  RCA  locus  were
genotyped as described previously [8,12,24,26,29].
Statistical analyses: All SNPs and copy number variant assays
were noted to be in Hardy–Weinberg equilibrium (p>0.05).
Single  variant  analyses  on  genotype  distributions  were
performed in SAS version 9.13 (SAS institute, Cary, NC)
using  logistic  regression  assuming  a  log-additive  genetic
model where variants were coded as 0, 1, or 2 for the number
of  minor  alleles  or  deletions.  Fisher’s  exact  tests  were
performed also on genotype distributions. Haplotype analyses
on  SNPs  across  the  RCA  locus  and  the  occurrence  of
CFHR3, CFHR1, CFHR4, and CFHR2 copy number variation
was performed using haplo.stats packages (Mayo Foundation
for Medical Education and Research) in R. To investigate the
effect of polymorphisms on AMD subtypes, each subtype was
compared to the control. Age is confounded with diagnosis
(i.e., the cases are older than the controls and age is a risk for
AMD),  thus  correction  for  age  might  have  unpredictable
effects;  all  analyses  were  performed  with  and  without
correction for age and gender [26]. Nominal p-values are
reported.
RESULTS
Development of a new MLPA assay: Ten samples from our
previous  paper  [12]  and  an  additional  two  male  and  two
female control samples were chosen for evaluating the new
MLPA assay (Figure 1). The new MLPA assay gave the same
results  for  the  four  loci  in  our  previous  assay
(CFHR3,CFHR1,SS18,  and  PDCD8)  [12],  which  was
reproducible  upon  running  the  assay  three  times.  The
reproducibility  of  the  capillary  electrophoresis  was
demonstrated by repeating this step twice. MLPA was also
performed  on  the  four  control  samples  with  different
oligonucleotide  combinations,  and  no  unwanted  probe
amplification (e.g., from the CFHR loci omitted from a given
assay) was observed. The products amplified by each of the
nine amplicons in the MLPA assay were electrophoresed on
agarose gels, and single bands of the expected product sizes
were observed.
Validation  of  ratio  change  thresholds  for  copy  number
variation  in  the  MLPA  assay:  Scatter  plot  diagrams
comparing  the  second  and  third  independent  assays  of
CFHR3, CFHR1, and CFHR4 of all samples were used to
define  our  MLPA  ratio  criteria  (Figure  2).  Based  on  this
evidence  and  the  replication  using  TaqMan  assays,  the
standard  MLPA  ratio  criteria  for  homozygous  deletion
(≤0.40),  heterozygous  deletion  (≤0.80),  and  heterozygous
duplication  (>1.60)  were  employed  throughout  the  study.
Examples of raw data are shown in Figure 3.
Copy number variation observed and association with AMD:
Eight unique combinations of deletions were observed. The
most common was the previously reported combined deletion
of CFHR3 and CFHR1 (Table 3). The second most common
was the combined deletion of CFHR1 and CFHR4 (Table 3).
More rare deletions are presented in Table 4. Unexpectedly,
no duplications were observed. We observed a significant
protective effect of the combined deletions of CFHR3 and
CFHR1 on risk of having AMD in both adjusted for age and
gender and unadjusted calculations (OR=0.47, 95% CI 0.36–
0.62). The effect was similar among different AMD subtypes
compared to the controls (OR=0.51, 95% CI 0.36–0.73 for
early AMD, and OR=0.43, 95% CI 0.31–0.62 for advanced
AMD). The 15 observed combined deletions of CFHR1 and
CFHR4  (eight  cases  and  seven  controls)  did  not  show  a
significant impact on risk of having AMD (Table 3 and Table
4).  The  other  deletions  were  also  observed  in  a  similar
Figure 2. Scatter plots comparing the copy number estimates determined for the second and third MLPA assay on all subjects. Panel A shows
the results for CFHR3, Panel B for CFHR1, and Panel C for CFHR4. The scatter plots show that the MLPA ratio criteria for homozygous
deletion is 0.00 to 0.40, for heterozygous deletion is 0.41 to 0.80, for wild-type is 0.81 to 1.60, and for heterozygous duplication is >1.60. The
largest cluster in each panel represents two copies, the second largest cluster one copy, and the subjects on the y-axis in panels A and B zero
copies.
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was seen in six cases and one control (Table 4).
Haplotype studies: Six common haplotypes were observed in
the RCA locus, following previous reports [10-12,30]. Three
haplotypes carried the Y402H polymorphism and increased
the risk of AMD (R1, R2, and R3), one haplotype was neutral
for AMD risk (N), and two haplotypes were protective (P1
and P2). The deletion of CFHR3 and CFHR1 was always
present on a haplotype most similar to P2 (Appendix 1 and
Appendix 2). SNP rs6677604 tagged the combined deletion
of  CFHR3  and  CFHR1,  as  reported  previously  [12].  The
rs6677604  GG  genotype  occurred  in  571  of  579  (99%)
Figure 3. Example of an MLPA copy number assay. Raw fluorescent intensity (y-axis, relative fluorescence units) observed during capillary
electrophoresis are illustrated. The first peak represents the amplicon of CFH intron 1 with a product size of 100 bp (x-axis, bp), followed by
the other probes as illustrated. The ratio of peak height of all probes to SS18 determines the copy number (see methods). CFHR2 always has
a high peak, which is taken into account with normalization. Therefore, this does not show a duplication of CFHR2. Panel A shows a wild-
type subject, panel B a subject heterozygous for deletion of both CFHR3 and CFHR1, and panel C a subject homozygous for deletion of both
CFHR3 and CFHR1. The X-chromosome marker (PDCD8) shows that all three subjects are females.
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.subjects without the combined deletion, the GA genotype in
189 of 189 (100%) subjects heterozygous for the combined
deletion, and the AA genotype in 25 of 25 (100%) subjects
homozygous  for  the  combined  deletion.  The  combined
CFHR1 and CFHR4 deletions and the CFRH2 only deletions
occurred on multiple independent haplotypes and were not
tagged by a single SNP.
DISCUSSION
We developed and validated a new MLPA assay to enable
determination of the frequency and patterns of copy number
variation in CFH and the five CFHR genes across the RCA
locus. The MLPA assay was performed on 813 subjects with
and without AMD. The well known combined deletion of
CFHR3 and CFHR1 was observed on 15% of chromosomes
in this study and was highly protective for AMD as reported
by us and others previously (Table 3) [10-13,30]. We were
able to verify that rs6677604 tags the combined CFHR3 and
CFHR1 deletion in a larger group of subjects than reported
previously [10,12,30]. So far no other tagging SNP has been
found for these copy number variations.
Copy  number  variation  in  the  human  genome  is
associated with many diseases [31-36]. It has been suggested
that  copy  number  variations  account  for  more  nucleotide
variations than do SNPs [37]. Due to their size copy number
variations often encompass functional DNA sequences and
can sometimes disrupt them [38] or lead to a protective effect.
The  combined  deletion  of  CFHR3  and  CFHR1  that  is
protective in AMD [10-13,30] is associated with an increased
risk for atypical hemolytic uremic syndrome [14,39,40]. The
combined  deletion  of  CFHR1  and  CFHR4  has  only  been
described  as  an  increased  risk  for  the  atypical  hemolytic
uremic syndrome [40]. Apart from the combined deletion of
CFHR3 and CFHR1 and of CFHR1 and CFHR4, we observed
an additional six patterns of deletions. However, these were
not sufficiently common to have a detectable effect on AMD
risk. Deletion of each CFHR gene was observed, except for
CFHR5. No duplications were detected, as would be expected
if the recombination events were common recurrent events.
Zhang et al. [17] also reported that there was a significant
association  between  variants  of  CFHR2  and  CFHR5  and
AMD  risk  and  showed  that  a  haplotype  spanning  CFH
(including the Y402H CFH variant), CFHR4, and CFHR2
was associated with the greatest risk of neovascular AMD
(p<10−6).  Narendra  et  al.  [16]  identified  five  different
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TABLE 4. SUBJECTS WITH CFH INTRON 1 AND EXON 18, CFH EXON 18 WITH CFHR3, CFHR3 ONLY, CFHR1 ONLY, COMBINED CFHR1 AND CFHR4, AND CFHR2
DELETIONS.
Final deletion count Demographics Diagnosis
CFH intron 1 CFH exon 18 CFHR3 CFHR1 CFHR4 CFHR2 Gender Age Affectation Subtype
1 0 0 0 0 0 F 77 Control  
1 0 0 0 0 0 F 66 AMD Early
0 1 0 0 0 0 M 82 AMD Exudative
0 1 0 0 0 0 M 72 Control  
0 1 1 0 0 0 F 69 Control  
0 0 1 0 0 0 M 65 Control  
0 0 1 0 0 0 M 85 AMD Exudative
0 0 0 1 0 0 F 70 Control  
0 0 0 1 1 0 F 66 AMD Exudative
0 0 0 1 1 0 F 43 AMD Early
0 0 0 1 1 0 F 79 AMD Early
0 0 0 1 1 0 F 89 AMD Exudative
0 0 0 1 1 0 M 68 AMD Exudative
0 0 0 1 1 0 M 88 AMD Exudative
0 0 0 1 1 0 F 63 Control  
0 0 0 1 1 0 F 71 AMD Early
0 0 0 1 1 0 M 66 Control  
0 0 0 1 1 0 F 86 AMD Exudative
0 0 0 1 1 0 F 82 Control  
0 0 0 1 1 0 F 61 Control  
0 0 0 1 1 0 F 65 Control  
0 0 0 1 1 0 F 71 Control  
0 0 0 1 1 0 M 79 Control  
0 0 0 0 0 1 M 81 AMD Early
0 0 0 0 0 1 F 90 AMD Exudative
0 0 0 0 0 1 M 78 AMD Exudative
0 0 0 0 0 1 F 84 AMD Early
0 0 0 0 0 1 F 65 AMD Early
0 0 0 0 0 1 M 68 Control  
0 0 0 0 0 1 M 71 AMD Exudativeheterozygous sequence changes in CFHR5 and suggested that
the mutant T allele in exon 4, which was significantly higher
in controls than in AMD patients (p<0.0001) and leads to a
codon  change  at  Asp169Asp,  might  be  associated  with  a
reduced risk of developing AMD. In a study of renal disease
(with  persistent  microscopic  hematuria,  recurrent
macroscopic hematuria, glomerulonephritis, and progressive
renal failure), Gale et al. [41] found a rare internal duplication
of exon 2 and exon 3 in CFHR5 that may account for the
substantial proportion of renal disease in Cyprus and called it
“CFHR5  nephropathy”  [41].  We  designed  our
oligonucleotide pair for MLPA within exon 7 of CFHR5 and
did not observe copy number variation within this region of
CFHR5 in our subjects. Narendra et al. [16] would not have
detected duplication of exons 2 and 3, and the effect of this
duplication on AMD is as yet unknown. Thus, variation in the
copy number of the CFHR genes is associated with atypical
hemolytic uremic syndrome and the CFHR5 nephropathy, but
a definitive association with AMD is still lacking.
We have observed extensive association between SNPs
across the RCA locus, including each of the CFHR genes,
since our original report in 2005 [8]. However, we have been
unable to demonstrate an effect independent of CFH using
statistical genetic approaches. The mechanism through which
the genetic variation across the RCA contributes to AMD
remains  a  subject  of  active  investigation.  Because  of  the
tendency of polymorphisms across this 300,000-bp and six-
gene  region  to  be  co-inherited  (linkage  disequilibrium),
independent effects of the genetic variation in this region is
difficult  to  assess  using  statistical  genetic  approaches.
However, haplotypes can be estimated across the region, and
the functional evaluation of these ancestral blocks of DNA has
proven insightful [24].
A small number of common haplotypes are found across
the CFH gene (Appendix 1) [6-8,12,42,43]. Depending on the
number  of  polymorphisms  included  in  the  estimation  of
haplotypes, there is a group of risk haplotypes (R1, R2, and
R3) that contain the Y402H polymorphism and increase the
risk  of  AMD.  Two  of  these  haplotypes  (R1,  R2)  appear
identical across the CFH gene, while R3 has some differences
after exon 14. The protective haplotypes (P1 and P2) appear
to protect against AMD, while the neutral (N) haplotype does
not have an impact on AMD risk.
We  previously  reported  that  each  of  the  common
haplotypes (R1, P1, P2, and N) had a distinct influence on the
activation and levels of complement in human blood [24].
Notably,  the  P1  haplotype  which  carries  the  I62V
polymorphism  reduced  complement  activation  in  human
blood [24] and biochemical functional studies [44,45], while
the R1, P2, and N haplotypes had no effect on blood levels of
complement  activation  [24].  These  two  observations  are
consistent  with  a  local  role  for  the  combined  deletion  of
CFHR3 and CFHR1 in decreased complement activation in
Bruch’s membrane and the choroid. Experimental studies are
needed to confirm the hypothesis noted earlier that deletion
of CFHR3 reduces competition with factor H inhibition of the
alternative pathway of complement. Our results suggest that
any such effect may occur on the surface of molecules of the
RPE, Bruch’s membrane, and choroid.
The combined deletion of CFHR3 and CFHR1 was a
consistent feature of the P2 haplotype. The combined deletion
of CFHR3 and CFHR1 appears to have arisen on the P2
haplotype, which can be defined by a C at rs3766404 and an
A at rs6677604 (Appendix 1 and Appendix 2). All but 22%
of the combined deletion of CFHR3 and CFHR1 reside on this
haplotype. The combined deletion of CFHR3 and CFHR1 was
always  observed  on  a  core  region  of  the  P2  haplotype
TAGAAGG from rs1061170 through rs1065489 (Appendix
2).  The  less  common  haplotypes  on  which  the  combined
deletion  of  CFHR3  and  CFHR1  reside  could  have  arisen
through  recombination  on  the  5′  region  of  CFH  (e.g.,
rs800292 or the functional I62V polymorphism) and SNPs far
downstream  of  CFH.  Notably,  the  results  provide  further
evidence that the protective effect mediated by the combined
deletion  of  CFHR3  and  CFHR1  is  independent  of  the
enhanced cofactor activity of the P1 haplotype provided by
the I62V polymorphism [24,44,45]. We found that the full P2
haplotype was found in combined deletion homozygotes of
CFHR3 and CFHR1 with a frequency of 53%, similar to
reports by Spencer et al. [30] (47%) and Hageman et al. [11]
(63%).
Raychaudhuri et al. [42] showed that Y402H is in linkage
disequilibrium with rs10737680 and the combined CFHR3
and CFHR1 deletion. By univariate analysis, they showed that
each marker has a significant association with AMD. When
they conditioned on Y402H alone, they demonstrated that the
combined deletion effect was still present. However, when
they conditioned on rs10737680, the statistical strength of the
protective effect of the combined deletion was alleviated.
Also, Neale et al. performed logistic regression to test if copy
number variations are associated with disease and found that
the CFHR1 deletion has a strong association with AMD but
that  it  does  not  describe  an  independent  association  [46].
However,  Hughes  et  al.  confirmed  by  logistic  regression
analysis  that  the  protective  haplotype,  which  includes  the
combined CFHR3 and CFHR1 deletion, confers a significant
independent effect on AMD [10]. Li et al. [47] demonstrated
that dissection of complex disease susceptibility loci is very
challenging and that even if the Y402H variant is strongly
associated with AMD, it is unlikely to be the only major
determinant of disease susceptibility in this region. The strong
linkage disequilibrium in this region limits statistical methods
to distinguish between alternative sets of associated SNPs.
The important question that we are trying to address is does
the P2 haplotype confer a protective effect beyond not having
the Y402H polymorphism. The P2 haplotype has no residual
impact on disease risk after statistical analysis conditioning
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functional  studies  (e.g.,  the  clear  impact  of  I62V  on
complement  levels)  [24]  that  statistical  analysis  does  not
always  capture  the  functional  variants.  Thus,  a  definitive
answer cannot be excluded without functional studies.
In summary, we observed that the combined deletion of
CFHR3  and  CFHR1  is  the  most  common  copy  number
variation across the RCA locus. The deletion is found on the
protective P2 haplotype, and we have confirmed that it can be
efficiently  tagged  by  the  single  nucleotide  polymorphism
rs6677604. The seven other deletions we observed are rare
and appear to have arisen on different haplotypes, suggesting
that direct genotyping of the deletions is needed for their
detection.
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2091Appendix 1. Common haplotypes across the RCA locus and haplotypes on
which deletions were observed.*
*The  combined  CFHR1  and  CFHR4  deletion  was
observed  in  15  subjects  on  the  following  haplotypes  in
descending frequency: a recombinant haplotype between R3
and either R1, R2 or P2, a recombinant R1/P1 haplotype, P1,
and a recombinant N/P1. The seven subjects with R2 deletions
occurred on 4 different haplotypes: P1, R1, a recombinant N/
R3, and R3. Note that 1 means present and 0 deleted. † The
combined CFHR3 and CFHR1 deletion is a consistent feature
of the P2 haplotype. ‡ The haplotype frequencies represent
the absolute frequency of the haplotype in the samples. To
access the data, click or select the words “Appendix 1.” This
will initiate the download of a compressed (pdf) archive that
contains the file.
Appendix 2. Common haplotypes across the RCA locus and haplotypes in
combined deletion homozygotes of CFHR3 and CFHR1.
* This is the P2 haplotype as described in Appendix 1. To
access the data, click or select the words “Appendix 2.” This
will initiate the download of a compressed (pdf) archive that
contains the file.
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